Related Image: Considering Revision Surgery? Board Certified Plastic Surgeon and Washington DC-based Dr. Mark E. Richards Pioneers Facelift Revisions Attracting Patients Worldwide |
(Date:7/3/2009)... Upstate HomeCare, a home medical services p...tion, respiratory and DME services, is expanding. ...ne specializes in home infusion therapy and one in...omeCare. , Clinton, NY (P...medical services provider specializing in infusion...
(Date:7/2/2009)... State Leaders to Support Principles to Govern Hea...ly 2 Nearly nine out of...mpanies have too much influence over how doctors c...voters support the concept of a "Health Insurer Co...ing principles for health insurance companies with...
(Date:7/2/2009)... Pro-life forces won an...Court ruled to uphold a state law regulating that ...es in administering RU-486 (also known as the "abo...en using the drug. , , The ruling came in Rog... Parenthood to a 2004 law requiring that those adm...
(Date:7/2/2009)...uly 2 A new analysis of...00 women between the ages of 0 to 84 from 2000 to ...ates issued by the Ministry of Health, with the sh...st group studied (ages 25 to 44). , , The new r...at track major breast surgeries rather than offici...
Breaking Medicine News(10 mins):Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3(Date:6/30/2009)... 30 , - "Study Could Have M...espect to Infertility Treatment" , New data... year,s,European Society of Human Reproduction an... the parameters of the simulation model used, the ...ighly-purified human menopausal,gonatropin or HP-...
(Date:6/29/2009)...rapeutics Based On Naturally Resected tRNA Synthet...ngu BioPharma, a subsidiary of aTyr Pharma in Hong...ent application on proprietary, naturally occurrin... synthetases are universal and essential component...nisms, human synthetases have naturally occurring ...
(Date:6/28/2009)...une 29 , - Study Triggers $...Group Corporation ("Sosei"; TSE Mothers Index: 456...nounce the commencement of a Phase III,clinical s...acting muscarinic,antagonist (LAMA) for the treat...PD). NVA237 is a dry powder formulation for oral i...
(Date:6/26/2009)...enetic Mutations Acting Together-- , , PHILADEL...es in the complex autism inheritance puzzle are em...cluding geneticists from The Children,s Hospital o...chool of Medicine and several collaborating instit... regions where rare copy number variations - missi...
Breaking Medicine Technology:New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203 4121 1Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203 4121 2Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203 4121 3Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203 4121 4Latest research on childrens issues featured at SRCD meeting 7821 1Corticon Shows Business Transformation Potential of Dialogs The First Intelligent Interactions Platform at April 23 Webinar 41425 1Corticon Shows Business Transformation Potential of Dialogs The First Intelligent Interactions Platform at April 23 Webinar 41425 2Corticon Shows Business Transformation Potential of Dialogs The First Intelligent Interactions Platform at April 23 Webinar 41425 3Don 26apos 3Bt Sacrifice Style Because of Sweat 41422 1Don 26apos 3Bt Sacrifice Style Because of Sweat 41422 2Don 26apos 3Bt Sacrifice Style Because of Sweat 41422 3Don 26apos 3Bt Sacrifice Style Because of Sweat 41422 4...SINESS WIRE)--Jun 26, 2007 - Insmed Incorporated,(...on the,development and approval of drugs for the t...needs, today noted the publication of,promising re...g the,potential role of insulin-like growth factor...blindness among premature infants., IGFBP-3 is a k...
...d SUNNYVALE, Calif., June 27, 2007,/PRNewswire-Fir...liminary results from two open-label, multi-center...use of Xcytrin(R),(motexafin gadolinium) Injection...tion with Alimta(R) (pemetrexed) and in,combinatio...eatment,for patients with non-small cell lung canc...
Other Medicine Technology:Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 2Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial
Dome shape, extra smooth tip provides safe insertion through wound & manipulation within the eye. 45, 4.0mm from end
BD Visitec Hydrodissection Cannulas
Medicine Products: